Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

* Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - * Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - * Appointment of Farrell Simon, Pharm.D., to the Board of Directors - HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform(™) drug optimization technology, today reported its financial results for the second quarter ended June 30, 2026, along with key business updates.

“We continued on our strategic plan, completing enrollment and dosing in Cohort 1 of the SER-252 registrational study ahead of our prior guidance,” said Steve Ledger, Chief Executive Officer of Serina. “Completion of Cohort 1 progresses the program to its next protocol-defined safety review and dose-escalation decision as we expect top-line data from the single-ascending-dose arm in the first half of 2027. We also strengthened the capabilities supporting SER-252 and the broader POZ Platform through our development partnership with Gannet BioChem and the appointment of Farrell Simon to our Board. Our near-term priority remains disciplined clinical execution and generating the data needed to evaluate whether SER-252 can deliver a differentiated product profile for patients with advanced Parkinson’s disease, where a high unmet need for more tolerable therapies continues to exist.”